About 15–20% of all breast cancers are human epidermal growth factor receptor-2 (HER-2)-positive, which used to be considered as an aggressive phenotype with poor prognosis until the development of anti-HER2 targeted therapy (2). This evidence concerns the gene ERBB2 and breast carcinoma.